spacer
home > ebr > winter 2002 > overview of the biotechnology industry in finland
PUBLICATIONS
European Biopharmaceutical Review

Overview of the Biotechnology Industry in Finland

Finland's knowledge-based growth strategy provides strong support for research and development, with investments in R&D having risen steadily since the early 1980s. In this respect, the most important recent event was the decision taken by the Government in 1996 to allocate funds from the privatisation of state-owned companies to fund science and technology. The goal was to increase the national R&D input to 2.9 per cent of GDP by 1999. Owing to rapidly increasing investment by the private sector, this level was achieved a year ahead of schedule. Today the figure, which is made up of public funding and the input from industry, has risen to 3.6 per cent. This puts Finland second in the world for R&D spending per capita. Of the total R&D investment, 29 per cent is funded by Government and 71 per cent by the private sector.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Sirkka Aura, CEO of Invest in Finland Sirkka Aura is Chief Executive Officer of Invest in Finland. Her particular expertise lies in the banking and financial sectors and is complemented by industry knowledge from a wide range of fields.
Prior to joining the IFB, Sirkka spent 12 years with Leonia Bank Oy in various posts including two years as Vice-President of their New York branch and several years as Manager of the bank's foreign corporate customers. She has an MSc from the Helsinki School of Economics and Business Administration.

spacer
Sirkka Aura
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

RSSL introduces same-day mycoplasma testing service in UK

Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and biopharmaceutical sectors, has introduced the United Kingdom’s first same-day mycoplasma testing service for manufacturers of biologic medicines.
More info >>

White Papers

The EC Definition of a Nanomaterial - Potential Measurement Methodologies

NanoSight

In October 2011 the European Commission published a definition of Nanomaterials. This move followed more than six years of scientific consideration of the potential toxicological and environmental challenges posed by engineered nanomaterials.
More info >>

 
Industry Events

PDA Parenteral Packaging 2019

19-20 March 2019, Hilton Molino Stucky, Venice, Italy

PDA Europe’s Conference has become a must-attend event for all professionals in the Parenteral Packaging arena. Join us in Venice in March 2019 to continue and further deepen scientific advancements and our ongoing professional discourse of latest on primary packaging technologies and business trends. This conference and the accompanying exhibition address quality of components and cont­ainers, container closure development and integrity testing as well as aspects of processing, product distribution and storage.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement